# IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer

> **NCT00234416** · PHASE1,PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 45 (—)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Gefitinib
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00234416
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-08
- **Primary completion:** —
- **Final completion:** 2005-03
- **Target enrollment:** 45 (—)
- **Last updated:** 2009-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00234416

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00234416, "IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00234416. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*